| Detected | Trial | Change |
|---|---|---|
| 2026-07-22 | NCT05577312 Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent… |
overall status: Enrolling by Invitation → Active, Not Recruiting |
| 2026-07-22 | NCT05577312 Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent… |
Trial sites expanded: 4 -> 7 locations |
| 2026-07-22 | NCT05577312 Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent… |
date change Primary completion pushed: 2026-08-20 -> 2026-10-20 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 1/2 | |||
| NCT05577312 | Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent… | Beta-Thalassemia | Active, Not Recruiting |
| Phase 1 | |||
| NCT05741359 | The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin… | Non-hodgkin Lymphoma,B Cell | Recruiting |
| NCT06633042 | The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of… | Autoimmune Disease | Not Yet Recruiting |
| Early Phase 1 | |||
| NCT06681337 | Universal CAR-T Cell Therapy for Refractory Lupus Nephritis | Lupus Nephritis | Not Yet Recruiting |
| Not specified | |||
| NCT06314529 | Long-term Follow-up Study of BHC001 for TDT | Thalassemia, Beta | Recruiting |
| NCT05988216 | Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | Recruiting |
| NCT07248163 | Universal CAR-T Cell Therapy for NHL | Non-hodgkin Lymphoma,B Cell | Recruiting |
| NCT07248176 | Universal CAR-T Cell Therapy for MM | Multiple Myeloma | Recruiting |
| NCT06298630 | Long-term Follow-up Study of BRL-101 for TDT | Thalassemia, Beta | Recruiting |
| NCT05859997 | Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases | Systemic Lupus Erythematosus (SLE) | Enrolling by Invitation |